Temozolomide – Antineoplastic Chemotherapy

Temozolomide is an antineoplastic cytotoxic agent belonging to the class of alkylating compounds derived from imidazotetrazine. It is considered the "gold standard" in the treatment of primary brain tumors due to its unique ability to effectively cross the blood-brain barrier and directly target neoplasm cells.

The mechanism of action involves the rapid chemical transformation of temozolomide at physiological pH levels into its active metabolite, MTIC (monomethyl triazeno imidazole carboxamide). The cytotoxic effect of MTIC is primarily due to the alkylation (methylation) of DNA, specifically at the O6 and N7 positions of guanine. This DNA damage triggers a cascade of aberrant repair processes, ultimately leading to DNA strand breaks and tumor cell death (apoptosis). The efficacy of the drug can depend on the methylation status of the MGMT gene promoter: patients with a "switched off" (methylated) MGMT enzyme typically show a more pronounced response, as the cells cannot repair the drug-induced damage.

The medication is intended for oral administration and possesses nearly complete bioavailability after ingestion.

Wikipedia page
Temozolomide

Indications

Temozolomide is indicated for the treatment of adult and pediatric patients in the following clinical scenarios:

  • Glioblastoma: newly diagnosed glioblastoma multiforme in adults (in combination with radiotherapy and subsequently as monotherapy).
  • Malignant Gliomas: recurrent or progressive forms of malignant gliomas (such as anaplastic astrocytoma) when standard therapy has failed.
  • Melanoma: as second-line therapy for metastatic malignant melanoma (in specific protocols).

Dosage and administration

The dosing regimen for temozolomide depends on the treatment phase and the patient's overall hematopoietic status.

  • Concomitant Phase: during radiotherapy, the drug is taken daily at a dose of 75 mg/m² of body surface area for 42 days.
  • Monotherapy (Maintenance Phase): administered in 28-day cycles. For the first 5 days of each cycle, the dose is 150–200 mg/m² once daily, followed by a 23-day break.
  • Administration Rules: capsules must be swallowed whole with a glass of water and should not be chewed. It is recommended to take the drug on an empty stomach (at least 1 hour before a meal), preferably at bedtime to reduce nausea.
  • Dose Adjustment: the dose may be reduced or treatment temporarily suspended if blood platelet or neutrophil counts drop significantly.

The use of temozolomide is restricted in the presence of the following factors:

  • Hypersensitivity: known allergy to temozolomide or dacarbazine (due to their similar chemical structure).
  • Myelosuppression: severe bone marrow suppression prior to starting the treatment course.
  • Pregnancy and Lactation: the drug has significant teratogenic and genotoxic potential; breastfeeding is prohibited.
  • Severe Renal or Hepatic Impairment: due to the lack of sufficient clinical experience in these patient groups.

Temozolomide therapy is frequently associated with side effects affecting various organ systems:

  • Gastrointestinal: nausea and vomiting (most common), constipation, diarrhea, and loss of appetite (anorexia).
  • Hematologic: decreased white blood cell (neutropenia) and platelet (thrombocytopenia) counts, increasing the risk of infection and bleeding.
  • Neurologic: headache, somnolence (drowsiness), fatigue, dizziness, and convulsions.
  • Dermatologic: rash, pruritus (itching), and alopecia (hair loss).
  • General: fever, chills, and general malaise.

Frequently Asked Questions

Temozolomide is an alkylating antineoplastic agent, a derivative of imidazotetrazine. Its uniqueness lies in its ability to easily cross the blood-brain barrier directly into the brain. Once in the body, it converts into an active compound that damages the DNA of cancer cells, inhibiting their ability to divide and leading to cell death.
Temozolomide is the standard treatment for newly diagnosed glioblastoma multiforme (in combination with radiotherapy and subsequently as monotherapy) and for recurrent malignant gliomas. It may also be used in the treatment of metastatic melanoma.
Capsules should be taken once daily at the same time each day, strictly on an empty stomach (at least 1 hour before a meal), with a glass of water. Taking the medication on an empty stomach helps minimize nausea and ensures proper absorption. The capsules must not be opened or chewed.
When temozolomide is taken in combination with radiotherapy, there is an increased risk of developing pneumonia caused by Pneumocystis jirovecii. In these cases, physicians often prescribe prophylactic antibiotics throughout the treatment course to protect the patient's immune system.
Temozolomide can cause myelosuppression (a decrease in platelet and white blood cell counts). Regular blood tests are mandatory, especially before starting each new treatment cycle. If platelet or neutrophil counts fall below a critical threshold, the medication may be delayed until blood levels recover to acceptable values.

List of medicines by active substance

-10%
Temoside 250 mg Cipla
View
Cipla

Temoside

Temozolomide
250 mg 5 capsules
4270₴ 4719₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00